Vicapsys Life Sciences, Inc. (VICP)
Vicapsys Life Sciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Suwanee, GA, US. The stock last traded at $1.45, up 0.00% on the session, giving a market capitalisation of $46.9M. On trailing twelve-month figures it carries a trailing P/E of -179.01, a net margin of 0.0%. Its beta of -4.13 implies it has historically moved less than the broad market.
Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive VICAPSYN product to market, guiding it through development and commercialization. This product's intended application is within the field of transplantation, specifically for various transplant therapies and associated stem-cell uses. Additionally, the company is advancing the development of VYBRIN, a compound based on CXCL12. VYBRIN is being investigated for multiple purposes: preventing the formation of post-surgical adhesions following abdominal operations, coating implantable medical devices and other implants to inhibit fibrosis, and promoting wound healing, with a particular emphasis on diabetic ulcers. The firm, originally incorporated in 1997, transitioned its name from Phage Therapeutics International, Inc. to Vicapsys Life Sciences, Inc. in September 2017. Its operations are headquartered in Suwanee, Georgia.
Vicapsys Life Sciences, Inc. is most often compared with the following Healthcare names: